The nation of Zimbabwe has turned down a substantial American health deal valued at $367m (272 million pounds) spanning five years because of the United States' request for sensitive data.
The decision became public after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
An official representative later clarified that the US was seeking genetic material for research and profit while refused to share the benefits from any future vaccines.
"We must now begin the challenging and unfortunate task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged continued dialogue to reach a agreement suitable to both sides so the country's critical HIV treatment initiative can proceed.
Wider Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a court halted a similar deal with the US after legal challenges were raised about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government agreements to boost transparency and responsibility.
As per statements, 16 African countries have so far agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, without any corresponding assurance of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research without any certainty that the final treatments would be available to our citizens if a new pandemic arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting structures already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This framework is designed to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how subsequent co-operation might be designed in a manner that respects the sovereignty and dignity of each country."
Health Experts Response
Medical experts stated it understood the official position, but suggested that talks need to persist considering much of the country's HIV programmes relied on external financing.
"Where specific concerns arise, including those involving data governance or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The situation highlights the complex debate between receiving much-needed international aid and safeguarding a country's data in an increasingly data-driven world.